The Analyst Verdict: Arcus Biosciences In The Eyes Of 5 Experts
5 analysts have shared their evaluations of Arcus Biosciences (NYSE:RCUS) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Arcus Biosciences, revealing an average target of $27.0, a high estimate of $32.00, and a low estimate of $20.00. Observing a 4.65% increase, the current average has risen from the previous average price target of $25.80.
Diving into Analyst Ratings: An In-Depth Exploration
The standing of Arcus Biosciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Emily Bodnar | HC Wainwright & Co. | Maintains | Buy | $32.00 | $32.00 |
| Eva Fortea Verdejo | Wells Fargo | Lowers | Equal-Weight | $23.00 | $30.00 |
| Richard Law | Goldman Sachs | Raises | Buy | $28.00 | $16.00 |
| Terence Flynn | Morgan Stanley | Lowers | Equal-Weight | $20.00 | $23.00 |
| Emily Bodnar | HC Wainwright & Co. | Raises | Buy | $32.00 | $28.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Arcus Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Arcus Biosciences compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Arcus Biosciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Arcus Biosciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Arcus Biosciences analyst ratings.
Discovering Arcus Biosciences: A Closer Look
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Arcus Biosciences's Economic Impact: An Analysis
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Arcus Biosciences's revenue growth over 3M faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately -45.83%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Arcus Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -519.23%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Arcus Biosciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -27.41%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Arcus Biosciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -13.18%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Arcus Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.25.
The Significance of Analyst Ratings Explained
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.